Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DLX105 in mild-to-moderate psoriasis vulgaris
NCT01936337Phase 2Completed
- Sponsor
- Delenex Therapeutics
- Start
- Aug 2013
- Primary completion
- Jun 2014
- Modality
- scFv Fragments, Hydrogel Systems
- Countries
- 2
01
Overview
A Phase 2 trial of DLX105 Hydrogel in Psoriasis vulgaris (PV), sponsored by Delenex Therapeutics. Started Aug 2013; status: completed.
02
Drugs
DLX105 Hydrogel
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT01936337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01936337.